Although glycemic control and diabetes duration are important predictors of retinopathy [1, 12] , genetic susceptibility also plays an important role in the pathogenesis of diabetic retinopathy [13] . Identification and characterization of genetic factors that predispose individuals to diabetic retinopathy could improve prevention and treatment measures for this debilitating condition. In the search for genetic elements that underlie diabetic retinopathy, we previously performed a genome-wide association study (GWAS) [14, 15] . An interesting finding generated from the analysis is the association of diabetic retinopathy with an SNP, rs11871508, in encoding family with sequence similarity 18, member B (FAM18B; gene ID 51030) also known as trans-Golgi network vesicle protein 23 homolog B (TVP23B). FAM18B is located on chromosome 17 [16] . The function of FAM18B is unknown. However, the protein encoded is expected to be an integral membrane protein. Given its association with diabetic retinopathy in our study, we sought to explore the possible role of FAM18B in diabetic retinopathy. Herein, we find that FAM18B is expressed in diabetic retinopathy-relevant tissues. We also demonstrate functional changes in human retinal microvascular endothelial cells with RNAi-induced downregulation of FAM18B. Overall, this study supports a role of FAM18B in the pathogenesis of diabetic retinopathy.
METHODS

Institutional review board approval:
The samples were obtained from all subjects through an approved institutional review board (IRB) protocol at the consenting institution. The use of human blood samples was approved by the University of Illinois, Chicago Institutional Review Board, and all participants gave informed consent to participate in the study. Since all patient health information was de-identified before genotyping and analysis, the IRB at the University of Illinois, Chicago, declared this portion of the study to be non-human subjects research.
Human subjects: Use of all human tissue conformed to the Declaration of Helsinki and the policies of the University of Illinois at Chicago. The subject characteristics are described in Table 1 . All participants underwent a complete medical history, and all subjects received an ophthalmic clinical evaluation. Participants included a study group consisting of subjects with proliferative diabetic retinopathy (PDR; n=8) and age-matched subjects with diabetes but without diabetic retinopathy (n=9; Table 1 ). The clinical diagnosis of proliferative diabetic retinopathy was defined as active neovascularization visible on the retina, tractional retinal detachment from fibrosis, or a diabetic vitreous hemorrhage in at least one eye. Age-matched diabetic controls were identified by an ophthalmologist as having no background diabetic retinopathy at the time of sample collection as well as no history of active neovascularization or diabetic macular edema.
Adult peripheral blood samples: Human peripheral blood samples were obtained from the subjects by venipuncture and collected in sodium heparin tubes (Vacutainer CPT; BD Labware, Bedford, MA). The tubes were prepared with a FICOLL Hypaque density fluid, allowing for separation of mononuclear precursor cells in a single step. Isolated mononuclear precursor cells were collected, washed twice, and resuspended in PBS (pH 7.4; Cat No# 14190250. Life Technologies, Carlsbad, CA).
Donor eyes:
Eyes from two post-mortem donors were used in this study. The retinal sections of the left eye of normal human donors were used in the study. The retinal sections of the human donors were obtained from the Illinois Eye Bank (Chicago, IL). Post-mortem donor eyes were supplied by Midwest Eye Bank (Ann Arbor, MI). ; 5'-AAT AAA GCT GCT GCT GAG CAA CCC-3' ) and GAPDH (5'-ACA TCG CTC AGA CAC CAT G-3'; 3'-TGT AGT TGA GGT CAA TGA AGG G-5') using power SYBR Green PCR master mix (Life Technologies). qPCR amplifications were performed for 40 cycles of denaturation at 95 °C for 15 s, annealing/extension 60 °C for 60 s as described by the manufacturer's instructions. The amplifications The melting curves were generated to detect the melting temperatures of the specific products immediately after the PCR run. Validated primers for each gene of interest were designed for each target mRNA. To ensure appropriate cycle time response, the primers were optimized, and the input cDNA levels were determined. Relative expression was calculated from the differences in the cycle time of an internal standard (glyceraldehyde 3-phosphate dehydrogenase; GAPDH) compared to the target mRNA. All qRT-PCR reactions used 40 ng of cDNA produced as described above and were run with two sets of triplicates.
Western blot analysis:
Following the treatments, the HRMECs were rinsed with cold PBS. The cells were collected in 1 ml PBS, collected in a microcentrifuge tube, and pelleted at 300 ×g for 10 min. The PBS was discarded, and the cells were lysed in 150 μl of lysis buffer (ProteoJET mammalian cell lysis reagent, Fermentas Life Sciences, Pittsburgh, PA) containing protease inhibitors (Roche, Diagnostics, Indianapolis, IN). Following lysis on ice for 20 min, the lysates were clarified with centrifugation at 300 ×g for 10 min. The protein content was estimated using the bicinchoninic acid Cell viability: HRMEC viability was determined using the CellTiter-Glo Luminescent cell viability assay kit (Promega, Madison, WI). The reagent determines the number of viable cells in culture by quantifying cellular ATP. The HRMECs were added to 96-well plates at a density of 20,000 cells/ well in 150 µl of MCDB 131 complete media. The cells were reverse transfected with FAM18B siRNA or negative control siRNA at a final concentration of 50 nM using the Lipofectamine RNAiMAX Transfection Reagent for 72 h. Following transfection, the cells were treated with media alone or media containing 50 ng/ml VEGF or 30 mM glucose.
To determine the role of NF-κB, cells were pretreated for 1 h with 50 µM pyrrolidine dithiocarbamate (PDTC, Sigma), a specific NF-κB inhibitor and for the remaining duration of the treatment. Following 48 h, the media was replaced with 100 µl of PBS and 100 µl of CellTiter-Glo reagent. The plates were placed on an orbital shaker for 2 min and then followed by 10 min at room temperature to stabilize the luminescent signal. The luminescence was measured to determine the ATP levels (Tecan Genios Pro, Tecan US, Morrisville, NC).
Cell migration assay: Cell migration was performed using a modified Boyden chamber method, as described previously [17] . HTS FluoroBlok 24-well cell culture inserts with 8 µm pore size (BD, Franklin Lakes, NJ) coated with gelatin-based coating solution on the lower surface were placed in companion 24-well tissue culture plates (Corning Inc., Corning, NY). FAM18B and control siRNA-transfected HRMECs were seeded in the upper chamber at a density of 50,000 cells/well in media alone. The lower chambers contained media alone as control, 50 ng/ml VEGF or 30 mM glucose as treatments. To determine the role of NF-κB, cells were pretreated for 1 h with 50 µM PDTC (Sigma), a specific NF-κB inhibitor, and for the remaining duration of the treatment. After 18 h of incubation at 37 °C, the culture inserts were removed and placed in 24-well plates containing 2 µM Calcein AM (BD Biosciences, Bedford, MA) in PBS. The cells were further at incubated 37 °C in calcein AM containing PBS for 1 h. Following incubation, the fluorescence in plates was measured with a spectroflurometer at excitation and emission wavelengths of 488 nm and 520 nm (Tecan Genios Pro).
Tube formation assay: A tube formation assay was performed as described previously [17] . Each well of the 96-well tissue culture plates (Costar; Corning) was coated with 50 µl of growth factor-reduced basement membrane matrix (BD Matrigel; BD Biosciences) [17] . FAM18B and control siRNAtransfected HRMECs were added to each well at a density of 20,000/100 µl/well. Serum-free and growth factor-free MCDB 131 media alone or media containing 50 ng/ml VEGF were added to the appropriate wells, and the cells were incubated at 37 °C for 6 h. To determine the role of NF-κB, the cells were pretreated for 1 h with 5,050 µM PDTC (Sigma), a specific NF-κB inhibitor, and for the remaining duration of the treatment. Tube formation was observed under a microscope (Zeiss 710). Images were captured, and the tube length was measured using ImageJ.
Statistical analyses: Data are presented as mean±standard deviation (SD) with statistical differences between groups analyzed with a standard two-tailed Student t test using Microsoft Excel software. A p value of less than 0.05 was considered statistically significant.
RESULTS
FAM18B
is expressed in the human retina: We evaluated the presence of FAM18B in the retina of human donor eyes. The distribution of FAM18B was assessed in the eyes of two normal donors without diabetes (Figure 1 ). Immunohistochemistry ( Figure 1B ,C) and immunofluorescence ( Figure  1E,F) revealed the presence of FAM18B in the human retina (red). FAM18B was distinctly colocalized with the retina vasculature. In particular, immunofluorescence demonstrated prominent staining in the retinal vasculature including capillaries, arteriole, and venules. The staining in the vasculature was confined to the endothelium. Staining for FAM18B was also observed in the choroidal vasculature. Retinal sections incubated with secondary antibody alone served as the control ( Figure 1A ,B was a decrease in the viability of control siRNA-transfected cells with high glucose, this was not significant. Cells transfected with FAM18B siRNA exhibited a significant reduction in viability by 50% when exposed to high glucose (p<0.05). The high glucose-induced decrease in viability in the FAM18B-depleted cells was significantly reversed by PDTC, a specific NF-κB inhibitor (p<0.05). These data suggest that the presence of FAM18B may help protect retinal endothelial cells from glucose-induced damage.
FAM18B downregulation affects human retinal microvascular endothelial cell migration: Migration of HRMECs was determined using a modified Boyden chamber assay. Migration of HRMECs transfected with scrambled control siRNA and treated with media alone served as the control. Migration across treatment groups was expressed as percent migration compared to control ( Figure 4A-C VEGF significantly increased tube formation in control cells; however, VEGF had no effect on tube formation in FAM18B siRNA-transfected cells. FAM18B expression is decreased in CD34+/VEGFR2+ cells: Eye tissue from post-mortem specimens may have altered gene expression profiles depending on the time of acquisition and the nature of storage [18] . Cells from the peripheral blood, such as CD34+/VEGFR2+ mononuclear cells, are easily accessible and can be obtained quickly and noninvasively. We sought to examine these circulating cells in subjects with proliferative diabetic retinopathy to confirm our in vitro FAM18B findings ( Figure 6 ). Previous studies exploring pathologic retinal angiogenesis suggest this population of mononuclear cells may contribute to pathologic retinal neovascularization thus making them a clinically relevant accessible peripheral population of cells in human patients [19] [20] [21] [22] [23] [24] [25] [26] [27] . There were no substantive differences between the study groups at baseline ( Table 1 ). The mean age (± SD) of subjects in the control group was 56.8 (± 14.6) while the mean age (± SD) of the subjects in the experimental group was 59.1 (± 12.4), yielding no significant age differences between groups (p=0.73). Gender (p=0.26) and ethnicity (p=0.62) similarly were not significant between the groups, with most subjects from both groups identifying as African American. Last, there was no significant difference between the groups in the duration of diagnosis of diabetes (p=0. 22) or recorded blood glucose level at last visit (p=0.06). The average diabetes duration (± SD) for the control subjects was 9.9 (± 6.5) years, and the mean time since diagnosis (± SD) for the study subjects was 18.3 (± 12.6) years. The average blood glucose level (BSL; ± SD) for the controls was 143.4 (± 36.7) mg/ dl, and the average BSL (± SD) for the proliferative diabetic retinopathy subjects was 195.6 (± 54.6) mg/dl. Although these differences were not significant, there was a general trend toward increasing diabetes duration and increasing basal sugar level in the proliferative diabetic retinopathy subjects. HbA 1 c levels were not used to determine glycemic control because they were not uniformly recorded for all subjects, and therefore, the BSL was the most consistent information available from a chart review regarding glycemic control.
CD34+/VEGFR2+ cells were isolated using f low cytometry (Figure 7) . Relative mRNA expression levels of FAM18B were compared in CD34+/VEGFR2+ cells from diabetic subjects with or without proliferative diabetic retinopathy. GAPDH mRNA was used as the internal standard for normalization. The expression levels as determined by the 2 -ΔΔc t values of FAM18B in diabetic patients with no retinopathy were 1.03±0.12, and the levels in diabetic patients with proliferative diabetic retinopathy were 0.81±0.11. The FAM18B expression levels were significantly decreased in the patients with proliferative diabetic retinopathy compared with the diabetes group without retinopathy (Figure 8 ; p<0.05). 
DISCUSSION
For the study of diabetic retinopathy, candidate gene studies were initially performed to evaluate genes in the major mechanistic pathways thought to be important in the development of microvascular complications associated with diabetes. To date, these studies have enjoyed limited success [28] [29] [30] [31] [32] . Strong evidence exists that there is a significant genetic component to diabetic retinopathy severity, yet to date, few genes or pathways have reliably been associated with the development of this disorder. We used a genome-wide association approach to agnostically implicate those critical genes and biologic pathways dysregulated in this condition [14] . FAM18B encodes for a membrane protein with unknown function. The gene was investigated in this study based on the association of a FAM18B intronic SNP, rs11871508, with diabetic retinopathy in our recent GWAS [14] .
Diabetic retinopathy significantly affects the normal functioning of retinal vasculature. Various mediators including hyperglycemia, AGEs, cytokines, and reactive oxygen species have been implicated in retinal microvascular injury. Associated ischemia and secondary hypoxia further drive the upregulation of angiogenic factors including VEGF that can result in angiogenesis and pathologic neovascularization seen in proliferative diabetic retinopathy.
Immunohistochemistry and immunofluorescence findings from this study demonstrate that FAM18B is expressed in the retina. Given the prominent endothelial immunolocalization, we investigated FAM18B expression in HRMECs. We observed that FAM18B expression was decreased in HRMECs exposed to various in vitro diabetic conditions, including high glucose, VEGF, or AGEs. To determine the functional role of FAM18B in HRMECs, we experimentally knocked down the levels of FAM18B with siRNA. Interestingly, we observed that the RNAi-mediated knockdown of FAM18B in HRMECs increased migration and endothelial tube formation. Importantly, we observed that VEGF or high glucose-induced migration was significantly potentiated in FAM18B-depleted HRMECs. We also observed that in the FAM18B-depleted cells, high glucose markedly exacerbated endothelial cell viability.
NF-κB is known to be upregulated in the setting of diabetes and plays a key role in its microvascular complications [33] [34] [35] [36] . A transcription factor with multiple functions, NF-κB has been implicated in mediating hyperglycemiainduced retinal endothelial cell death through apoptosis in diabetes and regulating VEGF levels and VEGF-induced angiogenesis in diabetic retinopathy [37] . VEGF, in turn, can activate proinflammatory NF-κB signaling and downstream effects such as the enhanced expression of adhesion molecules in endothelial cells and the secretion of inflammatory cytokines [8, 9] . We therefore explored the effects of NF-κB on the FAM18B-depleted endothelial cells using a specific NF-κB inhibitor, PDTC [38] [39] [40] . In our studies, we observed Figure 6 . Decreased FAM18B expression in CD34+/VEGFR2+ cells. Expression of FAM18B in CD34+/VEGFR2+ mononuclear cells from diabetic subjects with proliferative diabetic retinopathy is decreased compared to diabetic subjects without retinopathy. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was used as internal standard for normalization. DM: diabetes without diabetic retinopathy (n=9). PDR: diabetes with proliferative diabetic retinopathy (n=8). *p-value <0.05.
that NF-κB inhibition reversed the endothelial effects of FAM18B-mediated knockdown.
To better interpret these findings within the clinical context of diabetic retinopathy, we evaluated the expression of FAM18B in CD34+/VEGFR2+ mononuclear cells from individuals with proliferative diabetic retinopathy. Cells from the peripheral blood, such as CD34+/VEGFR2+ cells, are considered one of the circulating populations that may play a role in the normal physiology of the retinal capillary bed as well as its dysregulation in proliferative retinopathy [22, 24, 26] . CD34+/VEGFR2+ mononuclear cells in diabetic subjects demonstrate impaired proliferation and incorporation in vasculature thus limiting the normal repair of vasculature [41] . In advanced stages of proliferative diabetic retinopathy, these cells have been implicated in pathogenic neovascularization [42] . Interestingly, we observed the decreased expression of FAM18B in circulating CD34+/VEGFR2+ mononuclear cells obtained from subjects with proliferative diabetic retinopathy when compared to subjects with no diabetic retinopathy. Although FAM18B levels in CD34+/ VEGFR2+ mononuclear may not necessarily reflect its levels in the retinal endothelium, the low levels of FAM18B in the circulating cells in patients with proliferative retinopathy are consistent with our in vitro findings.
In summary, this is the first study to show the expression of the FAM18B protein in the human retina. We further have demonstrated that the expression of FAM18B is significantly decreased in human retinal microvascular endothelial cells when exposed to diabetic stimuli including high glucose and VEGF. Further, we demonstrated that RNAi-mediated downregulation of FAM18B enhances migration as well as endothelial tube formation in HRMECs and potentiates high glucose-induced endothelial cell death. Finally, we show that subjects with proliferative diabetic retinopathy exhibit reduced FAM18B expression. Thus, this study suggests a potential role for FAM18B in diabetic retinopathy. + mononuclear cells. Single positive controls and an unstained control were used to set the appropriate compensation values necessary to assign the double positive gating strategy (A, B, and C). Whole cells were separated from debris and doublets using the area and width pulses for forward and side scatter (D). The box identifies all double-positive cells that exhibit sufficient fluorescence of both markers to be identified-these were the cells that were sorted and collected.
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